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Systems biology approaches have recently provided new insights into the mechanisms 
of action of human vaccines and adjuvants. Here, we investigated early transcriptional 
signatures induced in whole blood of healthy subjects following vaccination with a 
recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the 
TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and 
correlated signatures to CN54gp140-specific serum antibody responses. Fourteen 
healthy volunteers aged 18–45 years were immunized intramuscularly three times at 
1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 
3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles 
were observed following immunization, ranging from over 300 differentially expressed 
genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional 
pathway analysis revealed blood transcription modules (BTMs) related to general cell 
cycle activation, and innate immune cell activation at early time points, as well as 
BTMs related to T cells and B cell activation at the later time points post-immuniza-
tion. Diverse CN54gp140-specific serum antibody responses of the subjects enabled 
their categorization into high or low responders, at early (<1 month) and late (up to 
6 months) time points post vaccination. BTM analyses revealed repression of modules 
enriched in NK cells, and the mitochondrial electron chain, in individuals with high or 
sustained antigen-specific antibody responses. However, low responders showed an 
enhancement of BTMs associated with enrichment in myeloid cells and monocytes as 
well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood 
mononuclear cells obtained from the subjects revealed an enhanced frequency of 
CD56dim NK cells in the majority of vaccines 14 days after vaccination as compared 
with the baseline. These results emphasize the utility of a systems biology approach to 
enhance our understanding on the mechanisms of action of TLR4 adjuvanted human 
vaccines.
Keywords: hiV vaccine, systems vaccinology, transcriptomics, adjuvant, glucopyranosyl lipid adjuvant-aqueous 
formulation, Tlr4
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inTrODUcTiOn
Since the onset of the epidemic, more than 70 million people 
have been infected with human immunodeficiency virus (HIV), 
and about 35 million people have died of HIV (1). An efficacious 
vaccine, alone or in combination with other interventions, is 
widely considered to hold promise for controlling the spread of 
HIV infection worldwide (2). Despite numerous efforts over the 
past three decades, an effective anti-HIV vaccine remains elusive. 
As exemplified in previous vaccine trials [reviewed in Ref. (3)], 
including the recent encouraging RV144 trial in Thailand (4), 
inter-individual variation in the immune response to HIV-1 is 
one of the several challenges for developing a broadly protective 
anti-HIV vaccine (5).
Antibodies directed against the viral Env protein are largely 
accepted to contribute to protection against HIV infection 
(6), though the nuanced involvement of different antibody 
classes or subclasses is unclear. Recent studies have shown that 
immunization with the stable trimeric recombinant HIV-1 
envelope glycoprotein, CN54gp140, induces strong systemic and 
mucosal immune responses following different immunization 
routes and strategies (7–9). In particular, immunization with 
this candidate antigen has induced potent humoral immune 
responses when adjuvanted with TLR4 agonist adjuvants, such 
as monophosphoryl lipid A (9) or GLA-AF (glucopyranosol lipid 
adjuvant-aqueous formulation) (10). These adjuvants are deemed 
to exert their adjuvanticity, at least in part, by activating the 
myeloid differentiation factor 88 (MyD88) and toll-interleukin 
1 receptor domain-containing adapter inducing interferon-β 
(TRIF) pathways (11–13). Nevertheless, the magnitude of elicited 
responses to CN54gp140 adjuvanted with GLA-AF are variable 
between individuals, the degree to which such variability could 
be contributed to difference in responsiveness to the adjuvant are 
unknown.
Early transcriptomics profiling has recently provided new 
insights into the mode of action of human vaccines and adjuvants 
(14–16), and has the potential to help elucidate mechanisms 
underlying diverse individual responses to identical vaccina-
tions. Systems biology was first used to identify gene signatures 
correlating with immune responses in humans following vaccina-
tion with the yellow fever vaccine YF-17D (17). Other studies 
have since then employed whole blood or peripheral blood 
mononuclear cell samples to evaluate gene expression signatures 
of human vaccines and correlate them with vaccine responses 
[for example (14, 18–20), and as reviewed in Ref. (15)]. Here, 
we employed whole genome transcriptomics combined with a 
systems biology approach with the aim of characterizing early 
molecular signatures induced in the whole blood of healthy 
volunteers vaccinated with an HIV-1 subunit vaccine candidate, 
composed of CN54gp140 adjuvanted with the TLR4 agonist 
GLA-AF. We herein report early transcript signatures and blood 
transcription modules (BTMs) in the whole blood within 7 days 
following vaccination. Further, we identified BTMs that were 
differentially enriched in high vs low serum CN54gp140-specific 
antibody responders. These results provide new insights into the 
early blood transcript signatures of TLR4 agonist-adjuvanted 
HIV-1 envelope glycoprotein vaccine candidates in humans.
MaTerials anD MeThODs
study subjects and Vaccine
Healthy male (n = 8) or female (n = 6) volunteers aged between 
18 and 45 and with no history of HIV-1 and HIV-2 infection were 
enrolled in an open label randomized clinical trial at Imperial 
College London, UK (study registered at ClinicalTrials.gov under 
registration no. NCT01966900). Informed written consent was 
obtained for all volunteers as part of the enrollment process. 
A recombinant uncleaved clade C HIV-1 envelope gp140 protein 
(CN54gp140) produced by Polymun Scientific (Klosterneuburg, 
Austria) to GMP specification, which has previously been reported 
to be immunogenic in a number of preclinical and clinical stud-
ies (7, 8, 21, 22), was used for the clinical trial. All subjects were 
immunized in the deltoid muscle three times at 1-month intervals 
with a vaccine candidate composed of 100 µg CN54gp140, adju-
vanted with 5 µg GLA-AF. Of the 14 recruited participants, 12 
went on to receive additional boosted immunizations at 6 (n = 6) 
or 12 (n =  6) months post their third priming immunization. 
More detailed information concerning study participants and 
design can be found in Ref. (23). Whole blood samples were 
taken for RNA analysis at the baseline (day 0) as well as at 6 h 
and 1, 3, and 7 days following first immunization (reported for 
this study only). This work was performed in compliance with UK 
Clinical Trial Regulations and all procedures were approved by 
the recognized Research Ethics Committee and by the Medicines 
and Healthcare Products Regulatory Authority.
rna samples
Whole blood samples were collected in PAXgene RNA stabiliza-
tion tubes (Qiagen, USA) from each participant before vaccina-
tion (day 0, 0 h) as well as at 6 h and 1, 3, and 7 days following 
first vaccination. RNA was extracted using the PAXgene Blood 
RNA kit, according to the manufacturer’s protocols (Qiagen, 
USA). Spectrophotometry was used to measure RNA concentra-
tion (ND-1000 spectrophotometer, NanoDrop Technologies Inc., 
USA) and the RNA integrity number (RIN), an indicator of sample 
quality, was determined using an Agilent 2200 TapeStation and 
2100 Expert Software (Agilent Technologies, USA). The RIN for 
the mRNA extracted from the remaining 66 whole blood samples 
ranged from 6.2 to 9.0 with a mean of 7.9 ± 0.6 for all extracted 
samples. Only samples with good quality mRNA, defined as hav-
ing a 260/280 ratio approximating 2 and RIN >7, were used in 
microarray analyses.
Microarray analysis and Data acquisition
Whole genome microarray analysis was performed at the 
Genomics Core Facility, University of Gothenburg, Sweden using 
an Illumina platform according to the manufacturer’s protocols. 
Briefly, the Fluorescent Linear Amplification Kit was used for 
RNA labeling, and quantity and labeling efficiency were verified 
prior to hybridization of samples to whole genome 8x60k human 
expression arrays (HumanHT-12 v4 Expression BeadChip kit; 
Illumina, USA). Post-hybridization scans were performed using 
an Agilent scanner at 5 µm and image analysis to generate raw 
data was completed using Feature Extraction software (version 
3Anderson et al. TLR4 Agonist-Adjuvanted Human Vaccine Signatures
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 301
11.5.1.1, Agilent Technologies). The raw data was pre-processed 
and normalized using the limma package and corrected for back-
ground using the “normexp” method in the statistical program R 
(24). Differentially expressed genes (DEGs) compared to baseline 
were identified by performing the moderate Student’s t-test at 
each of the time points (p-value) followed by further adjustments 
for multiple testing using the Benjamini–Hochberg method 
(adjusted p-value). Changes in expression at the four time points 
compared to baseline were calculated by subtracting the normal-
ized expression value of each individual transcript at baseline 
from that at the specified time point. Following microarray 
analysis, four samples were excluded from further analyses due 
to failed cRNA synthesis. In total, 62 high quality mRNA samples 
were included in further analyses (Figure S1A in Supplementary 
Material).
gene set enrichment analyses
Gene set enrichment analysis (GSEA) using the blood transcrip-
tion modules identified in Ref. (14) was applied to the data at 
each individual time point compared to baseline, using the GSEA 
software from the Broad Institute (25, 26).
Serum samples were obtained during the course of the study 
and concentrations of CN54gp140-specific serum IgM, IgA, and 
IgG (including subclasses IgG1, IgG2, IgG3, and IgG4) antibod-
ies were determined as previously described (23). Individuals 
were classified either as low or high responders based on early 
CN54gp140-specific IgM (14  days), IgG (28  days), and IgA 
(28 days) antibody concentrations, as well as on late antigen-spe-
cific serum antibody concentrations (168 days for IgA, IgG, IgG1, 
IgG2, and IgG4; 84 days for IgG3) (Figure S2 in Supplementary 
Material). These groupings were statistically validated using an 
unpaired Mann–Whitney test (at least p <  0.05 for all). GSEA 
using BTMs was applied as described above, to individual-level 
gene expression data for high or low antibody responders com-
pared to baseline, per antibody class or subclass.
antibodies
For phenotypic analysis of lymphocyte subsets by multi-color flow 
cytometry, PBMCs were stained with fluorochrome-conjugated 
antibodies for the surface markers CD3 (OKT3, Biolegend), 
CD4 (SK3, Biolegend), CD8 (SK1, Biolegend), CD14 (M5E2, 
Biolegend), CD19 (HIB19, Biolegend), CD56 (NCAM16.2, 
BD Biosciences), CD94 (DX22, Biolegend), CD161 (HP-3G10, 
Biolegend), CRACC (235614, R&D Systems) NKG2A (Z199, 
Beckman Coulter), NKp80 (MA152, Beckman Coulter), and 
TCRγδ (IMMU510, Beckman Coulter) as well as for intracel-
lular EOMES (WD1928, eBioscience), granulysin (GNLY) (DH2, 
Biolegend), NKG7 (2G9, Beckman Coulter), and PLZF (R17-809, 
BD Biosciences). Intracellular HOPX was detected with an 
unconjugated primary antibody (rabbit polyclonal, Proteintech) 
followed by a fluorochrome-labeled F(ab)2 anti-rabbit IgG sec-
ondary antibody (goat polyclonal, ThermoFisher). Dead cells 
were identified using a fixable live/dead stain (ThermoFisher).
Flow cytometry
Cryopreserved PBMCs from 0  h to 14  days were thawed, 
washed with cold RPMI-1640 (Gibco) supplemented with 10% 
FCS (Sigma-Aldrich) and labeled on ice with fluorochrome-
conjugated antibodies (Table S1 in Supplementary Material) and 
live/dead stain in FACS buffer (PBS supplemented with 2% FCS 
and 2  mM EDTA; all Sigma-Aldrich). Cells were then washed 
with FACS buffer, fixed at room temperature in PBS containing 
2% formaldehyde (Polysciences Inc.), permeabilized at room 
temperature in PBS with 0.1% Triton X-100 (Sigma-Aldrich) 
followed by intracellular staining performed in FACS buffer at 
room temperature. Samples were acquired on an LSRII Fortessa 
(BD Bioscience) and data analyzed and visualized using FlowJo 
software (v9.9.4; FlowJo, LLC), and GraphPad PRISM (v5.0). 
Gating strategy is shown in Figure S3 in Supplementary Material.
resUlTs
Overall changes in gene expression  
in response to Vaccination
Changes in expression at any time point following vaccination 
compared to baseline (0 h) were identified for 529 genes (adjusted 
p-value < 0.05, Table S2 in Supplementary Material), for which 
the peak number of uniquely expressed DEGs was observed at 
1  day post-first immunization (206 transcripts; Figure  1A). 
The majority of total DEGs were observed within 24  h post 
vaccination (329) compared to later time points (59 at 3  days 
and 24 DEGs at 7 days post-immunization). Of the transcripts 
uniquely and differentially expressed at the different time points 
compared to baseline, the lowest number was observed at 7 days 
post-immunization (24), reflecting a return to baseline within 
the observational period. The majority of DEGs identified at 6 h 
were downregulated compared to baseline (92/141, 65%), while 
at all other time points, the majority of DEGs were predomi-
nantly upregulated compared to baseline (220/323, 68% at 1 day; 
114/152, 75% at 3 days; and 79/93, 85% at 7 days) (Figures 1B–E).
The magnitude of observed group level transcriptional 
changes varied between time points compared to baseline 
(Figures 1B–F), and ranged between −1.132 log2FC and 2.220 
log2FC with the largest spread at 3 days (−0.696–2.220 log2FC). 
A total of 108 DEGs were identified to illustrate the largest fold 
change compared to baseline (>|0.500| log2FC, 67 upregulated 
and 41 downregulated DEGs) (Figure  1F). Of note, 21 genes 
appeared to switch from downregulated at 6  h to upregulated 
compared to baseline at later time points for most individuals. 
These included genes presumably involved in general response 
to vaccination, such as those related to tissue regeneration and 
hemoglobin (e.g., TMSB4X and HBE1), calcium signaling (e.g., 
CAMK2A and CAMK1G), and vesicle-mediated transport (e.g., 
NECAP2 and NRSN2) as well as specific immune-related genes 
(e.g., IL17REL, GDF1, and HLA-C) (27, 28).
Functional Differences in Transcriptional 
Profiles following Vaccination
We next identified functional pathways perturbed by the vaccina-
tion by performing a two-class comparison in GSEA to identify 
enriched blood transcription modules (BTMs), first presented in 
Ref. (14). Transcripts were ranked according to a fold change dif-
ference relative to the 0 h baseline, and only BTMs with an adjusted 
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FigUre 1 | Continued
FigUre 1 | Transcriptional changes in gene expression over time following vaccination. Subjects were intramuscularly immunized with CN54gp140 + GLA. In the 
Venn diagram, (a) the number of unique and shared differentially expressed genes (DEGs) in whole blood at 6 h, 1 day, 3 days, and 7 days after immunization 
(compared to baseline, 0 h) are shown, while the numbers and magnitudes (y-axis) of upregulated (red dots) or downregulated (blue dots) DEGs at 6 h (B), 1 day 
(c), 3 days (D), and 7 days (e), are depicted in volcano plots. An overview of all DEGs hierarchically clustered and arranged by time, are shown in a heat map (F), 
according to the color legend (upregulated DEGs in red, downregulated in blue, log2FC scale).
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p-value < 0.05 were considered significant. BTMs with weighted 
average of logFC for the different BTM forming transcripts 
being upregulated or downregulated are defined as enhanced or 
repressed, respectively. The enriched BTMs were divided into 
the following three main categories: cell cycle regulation and 
signaling; innate immune cells and activation, and lymphocyte 
activation and signaling (Figure  2; Table S3 in Supplementary 
Material). Some of the BTMs involved in cell cycle regulation 
and signaling were enhanced as early as 6 h following vaccination 
and remained enhanced until 7 days post vaccination, including 
regulation of transcription, transcription factors (M213), and cell 
cycle ATP binding (M144) demonstrating the immediate systemic 
impact of vaccination on general cell cycle pathways. BTMs rep-
resenting cell movement, adhesion, and platelet activation (M30) 
were repressed at all time points (Figure 2A). BTMs related to 
early immune responses, including toll-like receptors (TLR) and 
inflammatory signaling (M16), enrichment in neutrophils (I) 
(M37.1), and several BTMs related to enrichment in monocytes 
(M11.0, M118.0, S4) were significantly enhanced at 6 h compared 
to baseline (0 h), whereas most of these BTMs were not found to 
be significantly enriched at later time points (Figure 2B). BTMs 
belonging to lymphocyte signaling and activation, including T cell 
activation and signaling (M7.0, M19, S0), were mainly identified 
as enhanced at 1 and 3 days post vaccination. By comparison, the 
B cell modules (M47.0 and M69) were most highly enriched at 
6 h followed closely by 1 and 7 days post vaccination (Figure 2C). 
These results indicate enrichment of BTMs related to cell cycle 
regulation and signaling as well as those related to innate and 
adaptive immune responses following a single vaccination with 
the GLA-adjuvanted CN54gp140 vaccine candidate.
early BTM signatures induced in Whole 
Blood Post Vaccination correlate with 
later serum antibody responses
Next, we sought to study whether early transcript signatures cor-
related with later serum antibody responses. This was achieved 
by using GSEA to identify enriched BTMs in the transcriptomes 
of individuals grouped by their CN54gp140-specific antibody 
responses, at different time point post vaccination relative to the 
corresponding baseline. Individuals were divided statistically 
into high and low CN54gp140-specific serum IgM, IgG, or IgA 
antibody responders based on their serum antibody concentra-
tions and separation into groups was validated using statistical 
tests as described above (Figure S2 in Supplementary Material).
Individuals categorized as high IgM responders (day 14) 
exhibited a gene signature marked by a repressed enrichment of 
NK  cell-related genes (M7.2) at 3 and 7  days post-vaccination 
(Figure 3A). Genes including KLRB1, KLRD1, NKG7, SLAMF7, 
TBX21, and IL2RB contributed to the core NK cell enrichment 
and displayed downregulation compared to the baseline. In 
contrast, gene expression levels for low IgM responders at 6  h 
and 1 day exhibited enhancement in the BTM for “plasma cell 
surface signature” (S3) (Figure 3A), including genes SLC44A1, 
KCNH1, CAV1, TXNDC15, and KRTCAP2. The repression of two 
BTMs related to respiratory electron transport chain (mitochon-
drion) (M219, M238) marked early antigen-specific IgG and IgA 
responders, while enhancement of BTMs enriched for myeloid 
cells and monocytes (M81) at 6 h and 1 day post-vaccination were 
identified only in low IgG or IgA serum responders. Enhancement 
in the BTM, “integrin cell surface interactions” (M1.0) was also 
identified as another early BTM signature for low antigen-specific 
IgA responders.
Vaccinees were also categorized into high and low responders 
at later time points (up to 6 months post vaccination) based on 
their individual CN54gp140-specific serum antibody concentra-
tions (Figure S2 in Supplementary Material). Using this analysis, 
no specific BTMs were identified using the gene expression data 
from individuals classified as high or low serum IgG or IgG1 
responders. However, BTM-based gene signatures were identi-
fied which differentiated late high serum IgA, IgG3, and IgG4 
responders from low responders (Figure  3B). Notably, three 
NK cell-related enriched BTMs (M7.2, M61.0, and S1) were sig-
nificantly repressed in the gene expression profiles from individu-
als categorized as either late high serum IgA or IgG4 responders, 
including downregulation of many of the same genes indicated 
for early high IgM responders. Different BTMs were also signifi-
cantly enriched post-vaccination for individuals classified as late 
low IgA, IgG2, and IgG4 responders (Figure 3B). BTM module 
“Enrichment in myeloid cells and monocytes (M81)”, which was 
identified as significantly enhanced for low early serum IgG and 
IgA responders, was also identified as significantly enhanced for 
late low serum IgG2 antibody responders.
enhanced Frequency of cD3–cD56dim nK 
cells following Vaccination
Given tendencies for vaccination-induced enrichment in 
NK cell-related BTMs and significant associations between such 
NK cell-related BTMs modules and serum antibody responses, 
we next examined peripheral blood NK cells by flow cytometry 
in samples from subjects at 0 h baseline and at 14 days post first 
vaccination. Samples from intermediate time-points were not 
available. To determine whether observed changes in NK  cell-
related BTMs could be attributed to change in NK cell numbers or 
expression levels of proteins upon vaccination, we stained PBMC 
for lineage markers, NK cell receptors, and an array of proteins 
within regulated BTMs. Such proteins included transcription fac-
tors EOMES and HOPX, granule constituent’s GNLY and NKG7, 
as well as surface receptors CD161 (KLRB1), NKG2A (KLRC1), 
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FigUre 2 | Continued
FigUre 3 | Molecular signatures associated with early (a) and late (B) humoral responses. Blood transcription modules (BTMs) at early time points (6 h, 1 day, 
3 days, and 7 days) associated with IgA (measured at 14 days), IgG (measured at 28 days), and IgM (measured at 28 days) responses in high and low responders 
(a). BTMs at early time points (6 h, 1 day, 3 days, and 7 days) associating with IgA, IgG, IgG1, IgG2a, IgG3, and IgG4, all measured at 168 days except IgG3 
(measured at 84 days) responses in high and low responders (B). Size of the circles indicate level of significance [−log10(FDR)]. Only BTMs with FDR q value < 0.25 
are included in the plot. Negative association is indicated by blue color and positive association is indicated by red color.
FigUre 2 | Enrichment of blood transcription modules (BTMs) regulated upon vaccination. Spider web chart indicating enriched BTMs at 6 h (red), 1 day (yellow), 
3 days (blue), and 7 days (green). BTMs are functionally divided into: cell cycle regulation and signaling (a), innate immune cells and activation (B), and B and T cell 
activation and signaling (c). Only BTMs with FDR q values < 0.05 at at least one of the four time points (those time points are marked with asterisk) are considered. 
Points inside the dashed blue circle are negative enrichment and points outside the blue circle are positive enrichment.
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NKG2D (KLRD1), NKp80 (KLRF1), and CRACC (SLAMF7). 
Results showed an overall trend of increase in the frequency of 
CD3−CD56dim NK  cell population at 14  days post vaccination 
compared to the 0 h baseline (Figure 4). Levels of EOMES, HOPX, 
GNLY, NKG7, CD161, NKG2A, NKG2D, NKp80, and CRACC 
were not increased in CD3–CD56dim NK  cells at 14  days post 
vaccination (data not shown). In the limited number of analyzed 
samples, frequency of CD3–CD56dim NK  cell population in the 
blood of high antibody responder subjects was increased on 14 
days post vaccination compared to the 0 h baseline (Figure 4A). 
This was observed for all of limited number of the early IgM 
(Figure 4B), IgG, and IgA (Figure 4C) high responders, whereas 
three out of four (IgM), two out of four (IgG), and three out of 
five (IgA) of the low responders demonstrated a decrease of the 
CD3–CD56dim NK cell phenotype. Similar trends were observed 
when changes in NK  cells frequencies between baseline and 
14 days post vaccination were studied in vaccines defined as high 
versus low responders at later time points (Figure 4D).
DiscUssiOn
Herein, we employed a whole genome transcriptomics analysis 
combined with a systems biology approach to pinpoint early 
transcriptional signatures in whole blood of healthy volunteers 
FigUre 4 | Continued
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FigUre 4 | Frequency of CD56dim NK cell was enhanced in high antibody responders 14 days post vaccination. FACS plots showing NK cell populations of 
representative low (no IgM 14 days and low IgG 168 days) and high (IgM response 14 days and high IgG 168 days) responder before (D0) and 14 days following 
vaccination (a). Average frequency of the CD56bright and CD56dim NK cell populations at 0 h and 14 days (B). Log2 fold change of CD56bright and CD56dim NK cell 
population divided into IgM responders (Y) and non-responders (N) Day 14 following vaccination (c). Log2 fold change of CD56bright and CD56dim NK cell populations 
divided into early (84–168 days) high and low responders (IgG, IgG1, IgG2, IgG3, IgG4, and IgA) (D).
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vaccinated with the TLR4 agonist GLA-AF adjuvanted CN54gp140 
HIV-1 vaccine candidate. We identified DEGs and BTM signa-
tures of the whole blood response to the vaccine candidate up to 
7 days following vaccination, and the BTMs that showed correla-
tion with early and late CN54gp140-specific antibody responses.
We observed an increase in the number of DEGs compared 
to the baseline as early as 6  h post-vaccination, which peaked 
at 1 and 3  days followed by a decline to the expression levels 
comparable to that of baseline by 7  days. The observed kinet-
ics of the transcriptional changes in whole blood is in line with 
previous studies (15, 29). Notably, transcriptional analysis of 
the TLR4 agonist GLA adjuvant in mice revealed minimal gene 
regulation in blood compared with the site of injection (muscle) 
and draining lymph nodes (13), highlighting one of the major 
limitations of our and most human studies. A group of 21 genes 
were identified that demonstrated the greatest fold changes 
compared to baseline, and additionally appeared to switch 
from downregulated compared to baseline at 6 h to upregulated 
compared to baseline at later time points, for most vaccinated 
individuals. Several of these identified genes (such as TMSB4X 
and HBE1) were likely involved in the general response to vac-
cination, including hemoglobin genes and genes related to tissue 
regeneration. Of interest, all except three of the individuals had 
significantly increased HLA-C expression at D1, D3, and D7 
relative to the baseline. HLA-C belongs to the classical MHC 
molecules with least variability and recently it has been shown to 
interact with the Env protein of HIV (30), the antigen component 
of the vaccine used in our study. HLA-C is known to interact 
with two main ligands, the CD8 T cell receptor and even more 
efficiently with NK  cell receptors in an allele-specific manner, 
including: NKG2A/C immunoglobulin receptors (KIRs) and, to 
a lower extent, leukocyte immunoglobulin receptors (31, 32).
The functional pathway analysis of transcriptomics data with 
GSEA revealed BTMs related to general cell cycle activation, 
and innate immune cell activation at early time points, as well 
as BTMSs related to T cells, and B cell activation at the later time 
points. BTM offers an unprecedented possibility to function-
ally assess transcriptomic changes related to immunological 
responses in human blood (14). By statistically categorizing 
individual vaccines into high or low responder groups based on 
their CN54gp140-specific serum antibody levels, we identified 
several BTMs that were significantly enriched in either high or 
low responders for serum antibody classes and subclasses. In 
particular, we identified a repression in BTM modules related to 
NK  cells, especially at 3 and 7  days post-vaccination, for high 
serum IgM, IgA, and IgG4 antibody responders. Our finding is 
somewhat similar to a recent report, where the BTMs enriched 
in NK  cells and NK  cell surface signatures (M7.2, M61.0, and 
M61.2) were negatively associated with antibody titers in subjects 
that received the malaria vaccine candidate RTS,S (33) at day 56 
of their prime-boost regiment. Collectively, these data may sug-
gest an involvement of NK cells in negatively regulating humoral 
responses (34).
Notwithstanding, the flow cytometry analyses of the subjects’ 
PBMCs showed an increase in the frequency of CD3–CD56dim 
NK cells for 14 days post vaccination relative to the 0 h baseline. 
Unfortunately, the paucity of cellular samples from the subjects for 
1–7 days post vaccination prevented our further study of this phe-
nomenon. It is tempting to speculate that the repression of BTMs 
related to NK cells observed in the first 7 days post-vaccination 
reflects NK cells leaving the circulation early in the response. Given 
that NK cells are short lived, the enhanced frequency of NK cells 
for 14 days post vaccination is presumably attributed to second-
ary induction of NK  cell differentiation processes in response 
to vaccination. NK cells have been shown to inhibit generation 
of long-lived memory B  cells by suppressing follicular helper 
T cells during the first days of infection in mice (34). NK cells 
have previously been suggested to play an important role in the 
adjuvanticity of GLA-AF and GLA in squalene emulsion (SE) via 
rapid production of IFN-γ (35). It has also been hypothesized 
that vaccine-induced HIV-specific antibody-dependent cellular 
cytotoxicity mediated by healthy NK cell activity could help in 
preventing HIV infection (29). The vast majority of NK cells in 
the circulation is CD56dim NK  cells and considered cytotoxic, 
while around 10% are CD56bright NK cells and known to produce 
cytokines (36, 37). Vaccination with the inactivated influenza 
vaccine has previously been shown to downregulate membrane 
surface NKp46 cells on CD3−CD56dim NK  cells and increase 
NK cell-derived IFN-γ expression (38). Additionally, CD56bright 
NK  cells have been shown to increase following vaccination 
with a hepatitis B DNA vaccine, with significantly increased 
expression of CD244 and NKG2D, and correlating with specific 
T cell responses (39). However, NK cells are associated with both 
positive and negative regulation of humoral responses (40) and 
hence it is unclear if the observed repression in NK cells related 
BTMs has a direct causal role in enhancing humoral response 
to CN54gp140 adjuvanted with GLA, or is a surrogate of other 
regulatory events.
In this respect, it is intriguing that low early serum IgG and 
IgA responders were associated with the BTMs “Enrichment in 
myeloid cells and monocytes (M81).” The observed enhance-
ment of the BTMs for myeloid cells over those of NK cells in low 
responders may suggest potential differences in antigen handling 
and processing between low and high responders. Further, the 
enhancement in BTMs related to plasma cell enrichment in the 
low responders warrants further studies to pinpoint whether 
short-lived plasmablasts are being generated in preference to 
long-lived plasma cells in the low antibody responders.
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In line with the enriched upregulation of early plasma cell 
signature at 6  h and 1  day observed in the IgM antibody low 
responders in our study, the yellow fever vaccine showed an 
inverse correlation of antibody responses with plasma cell and 
B cell BTMs. Conversely, the immune responses to the trivalent 
influenza vaccine (TIV) and the quadrivalent meningococcal 
conjugate vaccine showed a positive correlation to those BTMs. 
Recently, significant correlations between the vaccine-induced 
antibody responses and plasmablast signatures following influenza 
vaccination (20) and interferon signaling following yellow fever 
and live attenuated influenza vaccinations (17, 20) were reported. 
These transcript signatures, however, did not show a significant 
correlation with the vaccine-induced antibody responses in our 
dataset. This is presumably explained, at least in part, by different 
mechanisms of action of the live attenuated vaccines and the 
TLR4 agonist-adjuvanted protein vaccines. In keeping with this 
notion, Li et al. reported different transcript signatures associat-
ing with vaccine-induced immune responses when five human 
vaccines of different modalities were compared (14). Therefore, 
it is plausible that while some of the blood transcript signatures 
are shared among different human vaccines, vaccines with dif-
ferent mechanisms of action may possess differential transcript 
signatures. Notwithstanding, we could not nevertheless rule out 
the possibility that some of the identified BTMs, e.g., the IgA 
correlating BTMs “expression of respiratory electron transport 
chain” and “elevated integrin cell surface interaction” merely play 
a surrogate rather than a causal role in the antibody responses. 
Further studies are needed to pinpoint the possible role of cor-
relating BTMs in the development and/or durability of antibody 
responses induced following vaccination in humans.
Altogether, we herein report potential transcript and BTM 
signatures of human whole blood in response to vaccination with 
the TLR4 agonist-adjuvanted CN54gp140 anti-HIV vaccine can-
didate. However, a few caveats should be applied to our findings. 
First, the small sample size suggests interesting observations that 
would require the execution of larger clinical studies to provide a 
greater statistical power. Second, PBMC samples from days 1–7 
were not available for detailed analysis of changes in the number 
and phenotype of circulating cells, thus observed transcriptomic 
changes may reflect differences in mRNA in circulating cells and/
or influx/efflux of cellular populations in the systemic circula-
tion. Nevertheless, these results provide new information on the 
candidate transcript signatures that may have potential as early 
biomarkers of antibody responses induced by TLR4 agonist-
adjuvanted HIV-1 Env vaccine candidates, and support the 
potential of systems approaches in providing new insights into 
underlying mechanisms of individual variation in response to 
vaccines in humans.
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